Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer: A case-control study

Digestion

Volumn 74, Issue 2, 2007, Pages 109-115

  Ranka, Satish ^a   Gee, Jenny M ^b   Johnson, Ian T ^b   Skinner, Jane ^c   Hart, Andrew R ^a   Rhodes, Michael ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b INSTITUTE OF FOOD RESEARCH   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Agonists; Calcium channel blockers; Lower oesophageal sphincter; Non steroidal anti inflammatory drugs; Oesophageal cancer

Indexed keywords

ACETYLSALICYLIC ACID; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CANCER RISK; CARDIA CARCINOMA; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN DEFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHODILATOR AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL SPHINCTER, LOWER; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 33846688030     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097947     Document Type: Article

References (47)

1. Cancer Incidence-UK, CRC Factsheet 1.1 (1998).
2. Cancer Incidence-UK, CRC Factsheet 1.1 (2002).
3. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr: Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404-1413.
4. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J: Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut 2004;53:1730-1735.
5. Lagergren J, Bergstrom R, Lindgren A, Nyren O: The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000;85:340-346.
6. Wu AH, Wan P, Bernstein L: A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721-732.
7. Chow WH, Blot WJ, Vaughan TL: Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-155.
8. Ogunwobi OO, Beales IL: Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006;134:105-113.
9. Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, Ahmed A, Day NE: A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 2000;83:127-132.
10. Sharp L, Chilvers CE, Cheng KK, McKinney PA, Logan RF, Cook-Mozaffari P, Ahmed A, Day NE: Risk factors for squamous cell carcinoma of the oesophagus in women: a casecontrol study. Br J Cancer 2001;85:1667-1670.
11. Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
12. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(suppl):39S-63S.
13. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH: A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003;88:684-688.
14. Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E: Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2004;2:880-887.
15. Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
16. Fitzgerald RC, Omary MB, Triadafilopoulos G: Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98:2120-2128.
17. Souza RF, Shewmake K, Terada LS, Spechler SJ: Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002;122:299-307.
18. Leu CM, Wong FH, Chang C, Huang SF, Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003;22:7809-7818.
19. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G: Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-496.
20. Barham CP, Alderson D: Pathophysiology and investigation of GORD and motility disorders; in Griffin SM, Raimes SA (eds): Upper Gastrointestinal Surgery. London, W.B. Saunders Co. Ltd. 2001, pp 251-282.
21. El-Serag HB, Graham DY, Satia JA, Rabeneck L: Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005;100:1243-1250.
22. El-Serag HB, Satia JA, Rabeneck L: Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut 2005;54:11-17.
23. Gelfond M, Rozen P, Gilat T: Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 1982;83:963-969.
24. Stein MR, Towner TG, Weber RW, Mansfield LE, Jacobson KW, McDonnell JT, Nelson HS: The effect of theophylline on the lower esophageal sphincter pressure. Ann Allergy 1980;45:238-241.
25. Wong RK, Maydonovitch C, Garcia JE, Johnson LF, Castell DO: The effect of terbutaline sulfate, nitroglycerin, and theophylline on lower esophageal sphincter pressure and radionuclide esophageal emptying in patients with achalasia. J Clin Gastroenterol 1987;9:386-389.
26. Zfass AM, Prince R, Allen FN, Farrar JT: Inhibitory beta adrenergic receptors in the human distal esophagus. Am J Dig Dis 1970;15:303-310.
27. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ: Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6:945-952.
28. Cheong E, Ivory K, Doleman J, Parker ML, Rhodes M, Johnson IT: Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 2004;25:1945-1952.
29. Mehta S, Johnson IT, Rhodes M: Systematic review: the chemoprevention of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2005;22:759-768.
30. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC: Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005;26:785-791.
31. Zhi H, Zhang J, Hu G, Lu J, Wang X, Zhou C, Wu M, Liu Z: The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 2003;106:327-333.
32. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
33. Lagergren J, Bergstrom R, Adami HO, Nyren O: Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133:165-175.
34. Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Rotterdam H, Dubrow R, Ahsan H, West AB, Blot WJ, Fraumeni JF Jr: Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998;7:749-756.
35. Corley DA, Levin TR, Habel LA, Buffler PA: Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol 2006;101:937-944.
36. Astarita C, Gargano D, Cutajar M, Napolitano A, Manguso F, Abbate GF: Gastroesophageal reflux disease and asthma: an intriguing dilemma. Allergy 2000;55(suppl 61):52-55.
37. Leggett JJ, Johnston BT, Mills M, Gamble J, Heaney LG: Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest 2005;127:1227-1231.
38. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
39. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A: Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther 2003;17:655-664.
40. Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Rotterdam H, Dubrow R, Ahsan H, West AB, Blot WJ, Fraumeni JF Jr: Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998;7:749-756.
41. Harding SM, Richter JE: Gastroesophageal reflux disease and asthma. Semin Gastrointestinal Dis 1992;3:139-150.
42. Sontag SJ, Schnell TG, Miller TQ, Khandelwal S, O'Connell S, Chejfec G, Greenlee H, Seidel UJ, Brand L: Prevalence of oesophagitis in asthmatics. Gut 1992;33:872-876.
43. DiMarino AJ Jr, Cohen S: Effect of an oral beta2-adrenergic agonist on lower esophageal sphincter pressure in normals and in patients with achalasia. Dig Dis Sci 1982;27:1063-1066.
44. Wyllie AH: Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 1993;67:205-208.
45. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL: Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1438-1447.
46. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-497.
47. Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, Herings RM, Hofman A, Coebergh JW, Leufkens HG, Stricker BH: Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer 2003;39:98-105.